... anthracycline-based (AB). The cardiotoxicity of AB regimens is especially relevant in the elderly population. Therefore, we retrospectively compared survival and toxicity between elderly patients with early TNBC receiving AB or anthracycline-free (AF) adjuvant chemotherapy to evaluate whether elderly patients...

... factor receptor 2 (HER2)-negative early breast cancer (EBC), adjuvant chemotherapy (ACT) is recommended in the case of high-risk features only. The MINDACT trial showed that patients with high clinical risk (CR) but low genomic risk (GR) defined by the 70-gene signature (MammaPrint®; 70-GS) did...

... with hormone receptor (HR)-positive and axillary node-negative tumors account for the largest proportion, which occurs in approximately half of invasive breast cancer in the United States [ 7 ]. Adjuvant chemotherapy (CT) is shown to reduce the risk of recurrence of early-stage breast cancer [ 8, 9 ]. However...

..., additional adjuvant chemotherapy plus regional hyperthermia was offered to all high-risk TNBC patients with non-pCR as part of routine management. All patients had operable, unilateral, primary invasive noninflammatory early stage I-IIIB TNBC (ER and PR <1%, HER2 score: 0 or 1) and no pathological...

...Marzia A. Locatelli; Giuseppe Curigliano; Alexandru Eniu Summary Triple-negative breast cancer (TNBC) represents a heterogeneous breast cancer subtype with a poor prognosis. The optimal adjuvant chemotherapy regimen is still unknown. Although numerous large randomized trials have established...

... for patients at risk. Patients with ≥ 4 positive lymph nodes should preferentially be treated with iddETC. Dose-dense Adjuvant chemotherapy Breast cancer Fig. 1 Strategies for improving the effectiveness of chemotherapy. Two very relevant points should be stressed before discussing...

...Ann H. Partridge Summary Evidence has long demonstrated that premenopausal women obtain the greatest benefit from adjuvant chemotherapy overall, with risk reduction increasing with decreasing age. The chemoendocrine effect of chemotherapy has only more recently been documented as impacting...

..., but this regimen could feasibly be adopted for the adjuvant chemotherapy. We conclude that the regimen of Buzdar et al. could be treated as an exception, although the NCCN has not accepted the feasibility of concurrent use of anthracycline and trastuzumab in ground rules. However, the NCCN also commented...

... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Adjuvant chemotherapy Elderly patients...

...Marc L. Citron The dose intensity of adjuvant chemotherapy for breast cancer is an important predictor of clinical outcome. Dose-dense chemotherapy increases the dose intensity of the regimen by delivering standard-dose chemotherapy with shorter intervals between the treatment cycles. The rationale...